Stephanie Nichols, PharmD, MPH, BCPP, BCPP, BCPS, FCCP | November 28, 2023 Do you struggle with knowing if a medication interaction is clinically meaningful? Do you get confused about which medications cause interactions and which are simply along for the ride? This session is devoted to reviewing pharmacokinetic CYP450 enzyme and P-glycoprotein transporter interactions using
November 29, 2023 | Amy M. Mayhew, MD, MPH This presentation will investigate cannabis use among adolescents and the associated risk factors for developing psychotic symptoms or a psychotic illness during adolescence. We will explore the impact of high-potency THC, the common perception of these substances as ‘natural’ and harmless, as well as the dose-dependent
What is Xylazine?
− A non-opioid agent that the FDA originally approved in 1972 as a sedative and analgesic for use in veterinary medicine (not FDA approved for use in humans)
− Acts as a central alpha-2-adrenergic receptor agonist in the brainstem (like clonidine)
o Rapid decrease in the release of norepinephrine and dopamine in the central nervous system (CNS)
o May also bind to other CNS receptors
Diagnosis and treatment of ADHD in adults with Substance Use Disorder: Applying Evidence to a Common Clinical Quandry
Diagnosis and Treatment of ADHD in Adults with Substance Use Disorder: Applying Evidence to a Common Clinical Quandary | November 10, 2022 | Andrea Truncali, Lauren Moran, and Margaret Chaplin
Diagnosis and treatment of adult ADHD is on the rise. Patients with substance use disorder are thought to be disproportionately affected by ADHD but how safe is, and what impact does the pharmacologic treatment have?
NEJM Knowledge+ Pain Management and Opioids consist of 62 in-depth, case-based scenarios developed by practicing clinician experts in pain management and addiction. The cases and questions assess the participant’s learning that includes many high-yield learning resources in the form of audio, video, and infographics. The material covers: The latest practices for assessing and managing acute
Facts About Buprenorphine FDA approved for Opioid Use Disorder treatment in an officebased setting. For those with tolerance to opioids as a result of OUD, buprenorphine is often a safe choice. Buprenorphine acts as a partial mixed opioid agonist at the μreceptor and as an antagonist at the κ-receptor. It has a higher affinity